Researchers at the University of Oulu have created a new method to analyze how individual patient tumor samples respond to drugs.This new pipeline is a major step towardpersonalized medicine because it addresses the difficulty in identifying the right drug, or combination of drugs, for each patient.
This pipeline uses live-cell barcoding to screen 96 drug treatments at single-cell resolution simultaneously.In a study focusing on high-grade serous ovarian cancer (HGSOC), the pipeline revealed the complex transcriptional landscape of tumors treated with 45 different drugs, representing 13 classes of mechanism of action.
Traditional cell line models often oversimplify the biology of real tumors, making it challenging to predict how a patient will respond to therapy.Working with primary patient samples not only improves the accuracy of these predictions but also opens the door to building a large-scale, data-driven “omics” database of drug responses.Researchers are hopeful that a comprehensive drug response database will significantly enhance the ability to match patients with the therapies most likely to be effective, ultimately improving outcomes in personalized cancer treatment.
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
